Zevra Therapeutics’ rare disease drug seems to be on the path to approval this fall after gaining the backing of an FDA advisory committee, although the experts were split, with some voting yes simply to address an unmet need.

BioNTech may still claim that the bispecific antibody acasunlimab has an “encouraging” clinical profile, but the mRNA leader has opted to end its involvement and allow partner Genmab to go solo for phase 3 trials.

Testmaker Cepheid plans to eliminate 626 staff positions at its Sunnyvale, California headquarters by September 27, according to a regulatory filing.

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program.

Vir Biotechnology’s second-quarter earnings report wasn’t short of big news. The company welcomed a trio of clinical-stage T-cell engagers (TCEs) from Sanofi while discarding a quarter of its workforce and a clutch of preclinical vaccine programs.

Veteran venture capital firm venBio has raised another half a billion dollars to invest in biotechs working on diseases with unmet needs. The $528 million raised for “Fund V” lines up nicely with the $550 million brought in for its fourth fund in 2021 and once again surpasses the comparatively paltry $394 million raised in 2020.

As the market for GLP-1 injections continues to grow, BD aims to ride that wave by providing drugmakers with its prefilled syringes.

After more than 30 years, gene therapy trailblazer James Wilson M.D., Ph.D., is leaving the University of Pennsylvania. He will be spearheading two new companies meant to translate the scientific discoveries made in the school’s Gene Therapy Program, where he served as director, into new treatments.

Instil Bio has been a biotech in search of a pipeline after it scrapped its lead assets over the last couple of years. Now, it seems to have found a pair of clinical-stage candidates from China to instill it with new purpose.

ALX Oncology’s phase 2 gastric cancer response rate has weakened. After seeing its CD47 blocker easily beat control over the first half of the trial, the biotech reported a much closer fight in the second part of the study—and investors were quick to send the stock spiraling downward.